| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0093-7754(01)90034-X |
| P698 | PubMed publication ID | 11740819 |
| P2093 | author name string | Adams J | |
| P433 | issue | 6 | |
| P304 | page(s) | 613-619 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | Proteasome inhibition in cancer: development of PS-341. | |
| P478 | volume | 28 |
| Q44195479 | 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells |
| Q93137228 | A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia |
| Q64096816 | A Practical Review of Proteasome Pharmacology |
| Q33380300 | A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy |
| Q40287113 | A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia |
| Q33366244 | A phase II study of bortezomib in the treatment of metastatic malignant melanoma |
| Q38897664 | A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line |
| Q53911086 | AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. |
| Q34696370 | Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells |
| Q46830755 | Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition. |
| Q35113656 | Advances in Molecular Therapies in Patients with Brain Tumors |
| Q35058958 | Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design |
| Q35603092 | Anticancer therapy targeting the apoptotic pathway |
| Q34690918 | Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo |
| Q35146577 | Apoptosis and melanoma chemoresistance |
| Q34520432 | Apoptosis: a link between cancer genetics and chemotherapy |
| Q46181614 | BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis |
| Q44542821 | Bortezomib |
| Q40359103 | Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits |
| Q39725130 | Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells |
| Q36521862 | Bortezomib for multiple myeloma |
| Q34252847 | Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice |
| Q42100170 | Bortezomib protects against dextran sulfate sodium‑induced ulcerative colitis in mice |
| Q43288668 | Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats |
| Q38787837 | Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells |
| Q39820073 | Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer |
| Q37714306 | Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents |
| Q35082170 | Cell-cycle dysregulation and anticancer therapy |
| Q30440490 | Cellular signaling molecules as therapeutic targets in glioblastoma multiforme |
| Q37170634 | Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics |
| Q38353590 | Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. |
| Q34198852 | Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis |
| Q34327233 | Development of the proteasome inhibitor Velcade (Bortezomib). |
| Q36592980 | Differential role of an NF-κB transcriptional response element in endothelial versus intimal cell VCAM-1 expression. |
| Q39655015 | Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity |
| Q35669458 | Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines |
| Q33289791 | Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison |
| Q36615301 | Endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity |
| Q34000612 | Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo |
| Q34179925 | Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis |
| Q36334327 | FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis |
| Q37348467 | Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency |
| Q39432161 | Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome |
| Q58562350 | Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach |
| Q48505281 | Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia |
| Q93003319 | Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability |
| Q83411634 | Multiple myeloma |
| Q30383428 | NCI-60 Cell Line Screening: A Radical Departure in its Time. |
| Q36709532 | NF-kappa B as a target for cancer therapy |
| Q35036569 | NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach |
| Q34774151 | New drugs in acute myeloid leukemia |
| Q39849716 | New targets of PS-341: BAFF and APRIL. |
| Q43943683 | Not just research tools--proteasome inhibitors offer therapeutic promise |
| Q37298880 | Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment |
| Q24298561 | Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells |
| Q34924231 | Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma |
| Q37381298 | Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo |
| Q37262591 | Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells |
| Q24315558 | Poly(A) binding protein (PABP) homeostasis is mediated by the stability of its inhibitor, Paip2 |
| Q38832181 | Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range |
| Q34754670 | Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer |
| Q37423426 | Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics |
| Q36408216 | Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review |
| Q37390575 | Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors |
| Q36995160 | Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload |
| Q35821602 | Proteasome inhibition in hematologic malignancies |
| Q39832776 | Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells. |
| Q35043552 | Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies |
| Q35036565 | RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer |
| Q34633196 | Regulation of apoptosis by the ubiquitin and proteasome pathway. |
| Q47738152 | Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies |
| Q39562856 | Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. |
| Q33713999 | Strategies to modulate immune responses: a new frontier for gene therapy |
| Q33629972 | Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors |
| Q36365504 | TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer |
| Q90706499 | The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors |
| Q29614975 | The NCI60 human tumour cell line anticancer drug screen |
| Q37129891 | The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. |
| Q38237360 | The Tao of myeloma |
| Q36414453 | The antidiabetic compound 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from Averrhoa carambola L., demonstrates significant antitumor potential against human breast cancer cells. |
| Q83204701 | The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B |
| Q38163937 | The effects of bortezomib on bone disease in patients with multiple myeloma |
| Q38674188 | The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis |
| Q46817722 | Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia |
| Q90460960 | UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy |
| Q50505041 | [Effect of bortezomib in inducing apoptosis of imatinib-resistant K562 cells and the mechanism]. |
| Q33530099 | beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor |
| Q28757630 | p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors |
| Q34191255 | p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells |
Search more.